ROSGQ Stock - Rosetta Genomics Ltd.
Unlock GoAI Insights for ROSGQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Revenue | $9.23M | $8.27M | $1.33M | $405,000 | $201,000 |
| Gross Profit | $1.79M | $2.00M | $17,000 | $-304,000 | $-57,000 |
| Gross Margin | 19.4% | 24.1% | 1.3% | -75.1% | -28.4% |
| Operating Income | $-15,664,000 | $-15,721,000 | $-14,252,000 | $-13,347,000 | $-8,267,000 |
| Net Income | $-16,233,000 | $-17,345,000 | $-14,526,000 | $-12,897,000 | $-10,457,000 |
| Net Margin | -175.8% | -209.8% | -1094.6% | -3184.4% | -5202.5% |
| EPS | $-9.31 | $-13.79 | $-15.51 | $-16.08 | $-28.20 |
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
Visit WebsiteEarnings History & Surprises
ROSGQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2018 | May 25, 2018 | — | — | — | — |
Q1 2017 | Mar 30, 2017 | $-1.38 | $-2.73 | -97.8% | ✗ MISS |
Q4 2016 | Dec 20, 2016 | $-1.98 | $-2.28 | -15.2% | ✗ MISS |
Q3 2016 | Sep 26, 2016 | $-2.08 | $-1.92 | +7.7% | ✓ BEAT |
Q2 2016 | May 19, 2016 | $-1.92 | $-2.16 | -12.5% | ✗ MISS |
Q4 2015 | Dec 1, 2015 | — | — | — | — |
Q1 2015 | Mar 16, 2015 | $-7.92 | — | — | — |
Q1 2015 | Mar 16, 2015 | $-7.92 | — | — | — |
Q3 2014 | Sep 17, 2014 | $-8.04 | $-7.92 | +1.5% | ✓ BEAT |
Q1 2014 | Mar 31, 2014 | $-5.94 | — | — | — |
Q3 2013 | Sep 9, 2013 | $-3.48 | $-8.16 | -134.5% | ✗ MISS |
Q1 2013 | Mar 22, 2013 | $-2.94 | — | — | — |
Q4 2011 | Nov 15, 2011 | $-37.80 | — | — | — |
Q2 2011 | Jun 1, 2011 | $-43.20 | $-57.60 | -33.3% | ✗ MISS |
Q4 2010 | Nov 30, 2010 | $-162.00 | $-144.00 | +11.1% | ✓ BEAT |
Q3 2010 | Sep 7, 2010 | $-134.40 | $-194.40 | -44.6% | ✗ MISS |
Q2 2010 | May 26, 2010 | $-140.40 | $-151.20 | -7.7% | ✗ MISS |
Q4 2009 | Dec 18, 2009 | $-180.00 | $-158.40 | +12.0% | ✓ BEAT |
Q3 2009 | Sep 8, 2009 | $-108.00 | $-302.40 | -180.0% | ✗ MISS |
Q2 2009 | May 21, 2009 | $-165.60 | $-194.40 | -17.4% | ✗ MISS |
Latest News
Frequently Asked Questions about ROSGQ
What is ROSGQ's current stock price?
What is the analyst price target for ROSGQ?
What sector is Rosetta Genomics Ltd. in?
What is ROSGQ's market cap?
Does ROSGQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ROSGQ for comparison